

PROTAC BRD4 Degradar-15 Biochemical

PROTAC BRD4 Degradar-15

CATALOG #
AAA228431


PRODUCT SYNONYMS

PROTAC BRD4 Degradar-15; PROTAC BRD4 Degradar-15 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2417370-67-1
Targets&IC50	BRD4 BD2:8.1 nM (IC50), BRD4 BD1:7.2 nM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTAC BRD4 Degradar-15 (compound 13)(4 h) inhibits suppresses MYC gene transcript in MV4-11 AML cells, with an IC 50 of 15 nM[1]. PROTAC BRD4 Degradar-15 (6 days) inhibits the proliferation of HL-60 and PC3-S1 cells, with an IC 50 of 4.2 nM and 91 nM[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Benzyl-PEG9-Ots, CAS 393517-91-4



Structure
Benzyl-PEG9-Ots, CAS 393517-91-4

ADDITIONAL INFORMATION

Related Product Information for PROTAC BRD4 Degradar-15 biochemical	PROTAC BRD4 Degradar-15 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC 50 s of 7.2 nM and 8.1 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degradar-15 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.
References	1. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-1014.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

